Lustra

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved January 1998

Specific Treatments:

ultraviolet-induced skin discolorations

Therapeutic Areas

General Information

Lustra has been approved for the treatment of ultraviolet-induced skin discolorations and hyperpigmentation associated with pregnancy, superficial trauma and the use of oral contraceptives and hormone replacement therapy.

Clinical Results

In clinical studies, Lustra demonstrated substantial reduction in pigmented lesions in a two-week period, and the reservoir effect of Lustra reduced damage from ultraviolet radiation versus placebo.

Mechanism of Action

Lustra contains 4% hydroquinone in a vehicle containing glycolic acid and an antioxidant complex.